EUVIMEDScopri EUVIMED
Übersichtsarbeit

Obstructive sleep apnea and metabolic syndrome

Sara Q C Giampá, Geraldo Lorenzi-Filho, Luciano F Drager

Obesity · 2023-04 · 31 (4) · 900-911

DOI: 10.1002/oby.23679 ↗

At a glance

Übersichtsarbeit in Obesity, published online on 2023-03-02. Written by Sara Q C Giampá and 2 co-authors. Institution: Graduate Program in Cardiology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. Major MEDLINE topics: Metabolic Syndrome, Insulin Resistance, Sleep Apnea, Obstructive. Cited 99 times so far (Crossref); 84 references. Funded by: FAPESP.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Metabolic syndrome (MS) is a heterogeneous condition associated with increased cardiovascular risk. There is growing evidence from experimental, translational, and clinical investigations that has suggested that obstructive sleep apnea (OSA) is associated with prevalent and incident components of MS and MS itself. The biological plausibility is supportive, primarily related to one of the main features of OSA, namely intermittent hypoxia: increased sympathetic activation with hemodynamic repercussions, increased hepatic glucose output, insulin resistance through adipose tissue inflammation, pancreatic β‐cell dysfunction, hyperlipidemia through the worsening of fasting lipid profiles, and the reduced clearance of triglyceride‐rich lipoproteins. Although there are multiple related pathways, the clinical evidence relies mainly on cross‐sectional data preventing any causality assumptions. The overlapping presence of visceral obesity or other confounders such as medications challenges the ability to understand the independent contribution of OSA on MS. In this review, we revisit the evidence on how OSA/intermittent hypoxia could mediate adverse effects of MS parameters independent of adiposity. Particular attention is devoted to discussing recent evidence from interventional studies. This review describes the research gaps, the challenges in the field, perspectives, and the need for additional high‐quality data from interventional studies addressing the impact of not only established but promising therapies for OSA/obesity.

Subjects

MeSH terms (MEDLINE)

Metabolic SyndromeInsulin ResistanceSleep Apnea, ObstructiveHumansCross-Sectional StudiesObesityHypoxia

Authors and institutions

  • Graduate Program in Cardiology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Laboratório do Sono, Divisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Unidade de Hipertensão, Instituto do Coração (InCor), Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Unidade de Hipertensão, Disciplina de Nefrologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

Funding

  • FAPESP

Cite

APA

Giampá, S. Q. C., Lorenzi-Filho, G., & Drager, L. F. (2023). Obstructive sleep apnea and metabolic syndrome. Obesity, 31(4), 900-911. https://doi.org/10.1002/oby.23679

Vancouver

Giampá SQC, Lorenzi-Filho G, Drager LF. Obstructive sleep apnea and metabolic syndrome. Obesity. 2023;31(4):900-911. doi:10.1002/oby.23679

BibTeX
@article{Giamp2023,
  author = {Giampá, Sara Q C and Lorenzi-Filho, Geraldo and Drager, Luciano F},
  title = {Obstructive sleep apnea and metabolic syndrome},
  journal = {Obesity},
  year = {2023},
  volume = {31},
  number = {4},
  pages = {900--911},
  doi = {10.1002/oby.23679}
}
Start for free →